Exploring how gut bacteria can enhance cancer treatment responses
Identifying gut bacterial molecules and mechanisms that promote an anti-tumor response to immunotherapy
This study is looking at how certain gut bacteria can help make cancer treatments work better, especially for patients receiving PD-1 therapy, by boosting the immune system's ability to fight tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10884884 on NIH RePORTER |
What this research studies
This research investigates the role of gut bacteria in improving the effectiveness of immunotherapy for cancer patients. It aims to identify specific bacterial molecules that can enhance the immune system's ability to fight tumors, particularly in response to PD-1 blockade therapy. The study will explore how these bacteria interact with immune cells in the gut and how these interactions can lead to a stronger anti-tumor response. By understanding these mechanisms, the research hopes to develop new therapeutic strategies that could benefit a broader range of cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing immunotherapy, particularly those who have not responded well to current treatments.
Not a fit: Patients with cancers that are not treated with immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the immune response in more patients.
How similar studies have performed: Previous research has shown promising results in understanding the gut microbiome's influence on cancer treatment responses, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Gazzaniga, Francesca Smylie — Harvard Medical School
- Study coordinator: Gazzaniga, Francesca Smylie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.